Please login to the form below

Not currently logged in
Email:
Password:

Amgen appoints CEO Robert Bradway to chair of board

Replaces Kevin Sharer who retires

Robert Bradway, AmgenAmgen's CEO Robert Bradway (pictured) has been named the company's chair of the board of directors, replacing Kevin Sharer who will retire at the end of the year.

The move follows Bradway's replacement of Sharer as Amgen's CEO in May, 2012, completing a succession process that was originally announced a year ago.

Bradway joined the company in 2006 as VP, operations strategy, before being appointed to executive VP and chief financial officer and then chief operating officer. Prior to joining the company, he was managing director of Morgan Stanley.

Sharer's departure ends his 20-year involvement with Amgen, including 12 years as CEO from 2000. During his time as head of the company, its annual revenue grew from $3.6bn to $16bn.

Bradway's appointment wasn't the only change at the top for Amgen, with director Vance Coffman appointed lead independent director.

"On behalf of the board and all of Amgen, we look forward to Vance Coffman's continued contributions as the new lead independent director," said Bradway, "and we thank Kevin Sharer for his 20 years of dedicated service and his contributions to the company and the patients we serve."

In addition, Amgen also announced the appointment of a new board member, with former CEO at toy company Mattel, Robert Eckert, to serve on the audit and corporate responsibility and compliance committees of the board.

"We are pleased to welcome Bob Eckert to the Amgen Board. Bob has significant experience and a superb track record of leading global companies during a long and successful career," said Bradway.

17th December 2012

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics